{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma+of+Skin&page=4", "query": { "condition": "Malignant Melanoma of Skin", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 1771, "total_pages": 178, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma+of+Skin&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma+of+Skin&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T18:19:05.672Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03724968", "title": "Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Advanced Melanoma", "Metastatic Melanoma Stratified by MHC-II Expression" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elizabeth Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2019-01-17", "completion_date": "2020-05-28", "has_results": true, "last_update_posted_date": "2021-04-20", "last_synced_at": "2026-10-07T18:19:05.672Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03724968" }, { "nct_id": "NCT04866810", "title": "The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Intervention Arm", "type": "BEHAVIORAL" }, { "name": "Control", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 24, "start_date": "2023-07-25", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-07T18:19:05.672Z", "location_count": 2, "location_summary": "Loma Linda, California • Bethesda, Maryland", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04866810" }, { "nct_id": "NCT07492680", "title": "A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "BMS-986504", "type": "DRUG" }, { "name": "Daraxonrasib", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab FDC", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2026-07-27", "completion_date": "2032-05-20", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-07T18:19:05.672Z", "location_count": 16, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07492680" }, { "nct_id": "NCT05026983", "title": "Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2021-12-27", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-07T18:19:05.672Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05026983" }, { "nct_id": "NCT05219578", "title": "RTX-224 Monotherapy in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Cutaneous Melanoma", "Head and Neck Squamous Cell Carcinoma", "Urothelial Carcinoma", "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "RTX-224", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rubius Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2022-01-12", "completion_date": "2022-11-30", "has_results": false, "last_update_posted_date": "2022-12-09", "last_synced_at": "2026-10-07T18:19:05.672Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05219578" }, { "nct_id": "NCT04035447", "title": "Symptom Management for YA Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer", "Young Adult", "Pain", "Psychological Distress", "Fatigue", "Breast Cancer", "Melanoma", "Hematologic Cancer", "Germ Cell Tumor", "Endocrine Cancer" ], "interventions": [ { "name": "Behavioral Symptom Management for Young Adult Cancer Survivors", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 65, "start_date": "2020-01-22", "completion_date": "2024-06-15", "has_results": true, "last_update_posted_date": "2025-06-29", "last_synced_at": "2026-10-07T18:19:05.672Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04035447" }, { "nct_id": "NCT03445533", "title": "A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Tilsotolimod with Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idera Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 481, "start_date": "2018-05-30", "completion_date": "2021-06-01", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-10-07T18:19:05.672Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03445533" }, { "nct_id": "NCT02819843", "title": "A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Merkel Cell Carcinoma", "Other Solid Tumors" ], "interventions": [ { "name": "TALIMOGENE LAHERPAREPVEC (TVEC)", "type": "DRUG" }, { "name": "Hypofractionated Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2016-06-21", "completion_date": "2024-02-22", "has_results": true, "last_update_posted_date": "2025-01-29", "last_synced_at": "2026-10-07T18:19:05.672Z", "location_count": 3, "location_summary": "Middletown, New Jersey • Harrison, New York • New York, New York", "locations": [ { "city": "Middletown", "state": "New Jersey" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02819843" }, { "nct_id": "NCT00715793", "title": "Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Hussein Tawbi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2008-06", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-10-03", "last_synced_at": "2026-10-07T18:19:05.672Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00715793" }, { "nct_id": "NCT00574977", "title": "Safety Study of Modified Vaccinia Virus to Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Breast Cancer", "Head and Neck Squamous Cell Cancer", "Liver Cancer", "Colorectal Cancer", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Vaccinia virus (vvDD-CDSR)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "David Bartlett", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2008-05", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2015-12-28", "last_synced_at": "2026-10-07T18:19:05.672Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00574977" } ] }